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ABSTRACT 
Objective: Synthesis of some novel bis [3-(aryl)-2-cyanoacrylamide], bis-pyrazole, bis-thiazole and bis-triazole derivatives starting from N,N'-
ethane-1,2-diylbis(2-cyanoacetamide) (1) to evaluate for their in-vitro antibacterial, antifungal and anticancer activities. 
Methods: Reaction of N, N'-ethane-1,2-diylbis(2-cyanoacetamide) (1) with different aromatic and heteroaromatic aldehydes yielded the 
corresponding bis[3-(aryl)-2-cyanoacrylamide] derivatives, which reacted with hydrazine hydrate to give N,N'-ethane-1,2-diylbis[3-amino-5-(4-
aryl)-1H-pyrazole-4-carboxamide] derivatives. Compound 1 reacted with each of thioglycolic acid, Phenyl isocyanate and elemental sulfur in 
presence triethylamine to give bis-thiazole derivatives. Diazotization of 1 with the desired diazonium chloride yielded the bis-hydrazone 
derivatives. The latter compounds refluxed with hydroxylamine hydrochloride and chloro- acetonitrile to give bis-triazole and bis-pyrazole 
derivatives respectively. 
Results: The structures of the newly synthesized compounds were confirmed by elemental analysis, IR, 1H NMR, [13]C NMR and mass spectral data. 
A total fourteen new synthesized compounds were evaluated for their in-vitro antibacterial, antifungal and anticancer activities against human liver 
cancer cell line (HEPG-2). 
Conclusion: The results obtained indicated that some of such compounds showed promising activities against Gram-positive, Gram-negative 
bacteria, fungi and anticancer activity in relation to the reference drugs ampicillin, gentamicin, Amphotericin B and vinblastine respectively. 
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INTRODUCTION 
Many compounds with pyrazole ring have been reported to exhibit 
diverse bioactivities such as antidepressant [1], anticonvulsant [2], 
antimicrobial [3], analgesic [4], anticancer [5] activity and also serve as 
human acyl-CoA: cholesterol acyltransferase inhibitors [6]. In addition, 
bis-heterocyclic compounds which contain pyrazole have rarely been 
reported. Also, Thiazole derivatives have been reported to possess 
several biological activities such as antimicrobial [7,8], anti-
inflammatory [9], antioxidant [10], anti-HIV [11] and antiallergic 
activities [12]. On the other hand, 1, 2, 4-triazole derivatives are 
potentially active anticancer [13], antiviral [14], anti-inflammatory 
[15], analgesic [16] and antidepressant [17]. In addition, recent reports 
indicate that bis-heterocycles displayed much better antibacterial 
activity than the mono heterocycles [18].  
In view of the above-mentioned observations and as continuation of our 
efforts in the synthesis of new biologically active heterocyclic compounds 
[19-30] we reported herein a facile routes for the synthesis of some 
novel bis[3-(aryl)-2-cyanoacrylamide], bis-pyrazole, bis-thiazole and bis-
triazole derivatives starting from N,N'-ethane-1,2-diylbis(2-
cyanoacetamide) (1) [30] as an excellent building block for the synthesis 
of the title compounds in order to investigate their biological and 
anticancer activities against a human liver cell line (HEPG-2). 
MATERIALS AND METHODS  
Melting points were determined on an electrothermal melting points 
Gallen-lamp apparatus is uncorrected. The IR (cm-1) spectra were 
measured on a Pye-Unicam SP300 instrument in potassium bromide 
discs. The 1H NMR and [13]C NMR spectra were recorded in CDCl3 or 
(CD3)2S on a Varian Mercury VXR-300 spectrometer (300 MHz) using 
TMS as an internal reference, and chemical shifts are expressed as δ 
palm units. Mass spectra were recorded on a GCMS-Q1000-EX 
Shimadzu and GCMS 5988-A HP spectrometers, the ionizing voltage 
was 70 eV. Elemental analyses were performed at the Microanalytical 
Center in Cairo University. Antibacterial, antifungal and anticancer 
activity assays were carried out in the Regional Center for Mycology 
and Biotechnology of Al-Azhar University, Cairo, Egypt. Compound 
N,N'-Ethane-1,2-diylbis(2-cyanoacetamide) (1) was prepared 
according to literature [30]. 
Synthesis of N,N'-ethane-1,2-diylbis[3-(aryl)-2-cyanoacrylamide] 3a-c 
General procedure To a solution of N,N'-ethane-1,2-diylbis(2-
cyanoacetamide) (1) (1.94 g, 0.01 mol) and the appropriate aromatic 
aldehydes 2a-c (0.02 mol of each) in dioxane (30 ml), was added a few 
drops of piperidine and the reaction mixture was heated under reflux 
for 6 h then left to cool. The solid product formed was collected by 
filtration, dried and then crystallized from DMF to afford the 
corresponding compounds 3a–c. 
N,N'-Ethane-1,2-diylbis[3-(4-(dimethylamine)phenyl)-2-
cyanoacrylamide] (3a) 
Yellow solid, from DMF, m. p.>300 °C, yield 68%. IR (KBr), ν = 3348 
(NH), 2197 (C≡N), 1660 (C=O) cm -1. 1H NMR [(CD3)2SO]: δ = 3.05 (s, 
12H, 4CH3), 3.58 (s, 4H, 2NCH2), 6.8 (d, 4H, J = 9.0 Hz, ArH), 7.85 (d, 4H, 
J = 9.0 Hz, ArH), 7.96 (s, 2H, 2CH), 8.18 (s, 2H, D2O-exchangeable, 2NH). 
[13]C NMR [(CD3)2SO]: δ = 37.80, 41.70, 75.88, 106.44, 121.11, 127.16, 
142.10, 159.18, 162.32, 171.20. MS m/z (%): 458 (M++2, 2.3), 457 
(M++1, 7.9), 456 (M+, 27.8), 455 (11.6), 241 (0.5), 199 (100). Anal. 
Calcd. for C26H28N6O2 (m/z, 456): C, 68.40; H, 6.18; N, 18.41. Found: C, 
68.37; H, 6.15; N, 18.40%. 
N, N'-Ethane-1, 2-diylbis[3-(4-nitrophenyl)-2-cyanoacrylamide] 
(3b) 
Orange crystals, from DMF, m. p.>300 °C, yield 66%. IR (KBr), ν = 3365 
(NH), 2216 (C≡N), 1679 (C=O) cm-1. 1H NMR [(CD3)2SO]: δ = 3.43 (s, 4H, 
2NCH2), 8.12 (d, 4H, J = 9.0 Hz, ArH), 8.3 (s, 2H, 2CH), 8.38 (d, 4H, J = 
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9.0 Hz, ArH), 8.71 (s, 2H, D2O-exchangeable, 2NH). [13]C NMR 
[(CD3)2SO]: δ = 41.72, 75.79, 78.80, 80.82, 108.77, 113.93, 133.68, 
140.41, 168.99. MS m/z (%): 460 (M+, 0.9), 459 (0.9), 243 (58.8), 201 
(100), 184 (16.3), 155 (67.7), 127 (50.4), 100 (20.5), 76 (23.6). Anal. 
Calcd. for C22H16N6O6 (m/z, 460): C, 57.39; H, 3.50; N, 18.25. Found: C, 
57.39; H, 3.54; N, 18.22%. 
N,N'-Ethane-1,2-diylbis[3-(1,3-diphenyl-1H-pyrazol-4-yl)-2-
cyanoacrylamide] (3c) 
Yellow solid, from DMF, m. p. 282, yield 57%. IR (KBr), ν = 3435 (NH), 
2201 (C≡N), 1681 (C=O) cm -1. 1H NMR [(CD3)2SO]: δ = 3.37 (s, 4H, 
2CH2), 7.44-7.52 (m, 12H), 7.53-7.65 (m, 4H), 7.92-7.95 (m, 4H), 8.05 
(s, 2H), 8.49 (s, 2H), 9.14 (s, 2H, 2NH). MS m/z (%): 655 (M++1, 3.2), 
654 (M+, 8.0), 327 (27.5), 219 (1.7), 77 (100). Anal. Calcd. for 
C40H30N8O2 (m/z, 654): C, 73.38; H, 4.62; N, 17.11. Found: C, 73.32; H, 
4.61; N, 4.60%.  
N,N'-Ethane-1,2-diylbis[3-amino-5-(4-aryl)-1H-pyrazole-4-
carboxamide] (4a-c) 
General procedure To a solution of the appropriate bis-acrylamide 3a-c 
(0.01 mol) in ethanol (30 ml), hydrazine hydrate (80%, 4 ml, 0.02 mol) 
was added. The reaction mixture was heated under reflux for 5 h then 
left to cool. The solid product so formed was filtered, washed with 
EtOH, dried and then crystallized from the appropriate solvent. 
N,N'-Ethane-1,2-diylbis[3-amino-5-(4-(dimethylamine)phenyl)-
1H-pyrazole-4-carboxamide] (4a) 
Yellow solid, from DMF, m. p.>300 °C, yield 60%. IR (KBr), ν = 3315, 
3189 (NH, NH2), 1678 (C=O) cm-1. 1H NMR [(CD3)2SO]: δ = 3.08 (s, 12H, 
4CH3), 3.31 (s, 4H, 2CH2), 6.87 (s,4H, 2NH2), 7.35 (d, 4H, ArH), 7.94 (d, 
4H, ArH), 9.47 (s, 2H, 2NH), 10.39 (s, 2H, 2NH). MS m/z (%): 518 
(M++2, 1.1), 517 (M++1, 3.2), 516 (M+, 5.6), 276 (35.8), 230 (14.8), 77 
(100). Anal. Calcd. for C26H32N10O2 (m/z, 516): C, 60.45; H, 6.24; N, 
27.11. Found: C, 60.40; H, 6.20; N, 27.10%. 
N,N'-Ethane-1,2-diylbis[3-amino-5-(4-nitrophenyl)-1H-pyrazole-
4-carboxamide] (4b) 
Yellow crystals, from DMF, m. p.>300 °C, yield 78%. IR (KBr), ν = 3429, 
3086 (NH, NH2), 1689 (C=O) cm-1. 1H NMR [(CD3)2SO]: δ = 3.65 (s, 4H, 
2CH2), 7.21 (s, 4H, 2NH2), 7.48 (d, 4H, ArH), 7.88 (d, 4H, ArH), 9.51 (s, 
2H, 2NH), 10.29 (s, 2H, 2NH). MS m/z (%): 522 (M++2, 3.8), 520 (M+, 
8.4), 518 (M+-2, 22.5), 246 (10), 205 (27.5), 176 (97.5), 77 (100). Anal. 
Calcd. for C22H20N10O6 (m/z, 520): C, 50.77; H, 3.87; N, 26.91. Found: C, 
50.73; H, 3.82; N, 26.88%. 
N,N'-Ethane-1,2-diylbis[5-amino-1',3'-diphenyl-1'H,2H-3,4'-
bipyrazole-4-carboxamide] (4c) 
Yellow, from DMF, m. p.>300 °C, yield 55%. IR (KBr), ν = 3427, 3320 
(NH, NH2), 1671 (C=O) cm-1. 1H NMR [(CD3)2SO]: δ = 3.30 (s, 4H, 
2NCH2), 7.37 (s, 4H, 2NH2), 7.39-7.55 (m, 12H, ArH), 7.60-8.00 (m, 10H, 
ArH), 9.19 (s, 2H, 2NH), 9.47 (s, 2H, 2NH). MS m/z (%): 716 (M++2, 
1.8), 714 (M+, 6.5), 637 (15), 560 (35), 494 (27.5), 493 (56), 416 (85), 
175(45), 77 (100). Anal. Calcd. for C40H34N12O2 (m/z, 714): C, 67.21; H, 
4.79; N, 23.52. Found: C, 67.18; H, 4.77; N, 23.50%. 
N,N'-Ethane-1,2-diylbis[2-(4-oxo-4,5-dihydrothiazol-2-yl) 
acetamide] (6) 
A mixture of compound 1 (1.94 g, 0.01 mol) and thioglycolic acid (1.84 
g, 0.02 mol) in acetic acid (40 ml) was heated to reflux for 3 h then left 
to cool. The formed solid product was collected by filtration, washed 
with ethanol, dried and then crystallized to give compound 6. Yellow 
crystals, from DMF, m. p. 296 °C, yield 56%. IR (KBr), ν = 3397 (NH), 
1716 (C=O), 1635 (C=O) cm-1; 1H NMR [(CD3)2SO]: δ = 3.12 (s, 4H, 
2CH2), 3.59 (s, 4H, 2NCH2), 5.56 (s, 2H, 2CH), 7.72 (s, 2H, 2NH), 11.23 
(s, 2H, 2OH); MS m/z (%): 342 (M+, 7.1), 341 (7.8), 171 (14.9), 99 (2.8). 
Anal. Calcd. for C12H14N4O4S2 (m/z, 342): C, 42.09; H, 4.12; N, 16.36; S, 
18.73. Found: C, 42.05; H, 4.10; N, 16.29; S, 18.71%. 
N,N'-Ethane-1,2-diylbis(4-amino-3-phenyl-2-thioxo-2,3-
dihydrothiazole-5-carboxamide) (7) 
To a solution of compound 1 (1.94 g, 0.01 mol) in EtOH containing 
triethylamine (1 ml), elemental sulfur (0.64 g, 0.02 mol) and phenyl 
isothiocyanate (2.72 g, 0.02 mol) were added to the resulting mixture 
was heated at 60 oC for 2h, under continuous stirring, then cooled and 
neutralized by pouring onto ice/water mixture containing a few drops 
of hydrochloric acid. The precipitate formed was collected by filtration, 
washed with EtOH, dried and then crystallized to give product 7. 
Yellow solid, from EtOH-DMF, m.p. 282 °C, yield 66 %. IR (KBr), ν = 
3437, 3367, 3250 (NH, NH2), 1618 (C=O) cm-1. 1H NMR [(CD3)2SO]: δ = 
3.28 (s, 4H, 2CH2), 6.70 (s, 4H, 2NH2), 7.33-7.36 (m, 4H), 7.57-7.65 (m, 
8H, ArH+2NH). MS m/z (%): 530 (M++2, 0.6), 529 (M++1, 0.9), 528 (M+, 
2.4), 321 (1.1), 264 (1.9), 207 (6.4), 77 (100). Anal. Calcd. for 
C22H20N6O2S4 (m/z, 528): C, 49.98; H, 3.81; N, 15.90; S, 24.26. Found: C, 
49.95; H, 3.80; N, 15.89; S, 24.22%. 
Coupling of compound 1 with the appropriate diazonium salt of 
aromatic amines 
General procedure To a cold solution of compound 1 (1.49 g, 0.01 Mol) 
in ethanol (50 ml), in the presence of sodium acetate trihydrate (3 g), 
was added the appropriate diazonium salt of aromatic amine (4-
methylaniline or methyl 4-aminobenzoate) (0.02 mol), (prepared 
according to literature procedures [31]). The addition was carried out 
portion wise with continuous stirring at 0-5 oC over a period of 1 h. 
After complete addition, the reaction mixture was stirred for further 
4h and finally diluted with water. The precipitated solid formed was 
collected by filtration, dried and then crystallized from the dioxane to 
give the corresponding coupling products 9a,b. 
N,N'-Ethane-1,2-diylbis[(2-(4-methylphenyl)hydrazono)-2-
cyanoacetamide] (9a) 
Yellow crystals, from dioxane, m. p. 251 oC, yield 80%; IR (KBr), ν = 
3315, 3235 (2NH), 2925 (aliphatic CH), 2212 (C≡N), 1645 (C=O) cm -1. 
1H NMR [(CD3)2SO]: δ = 2.26 (s, 6H, 2 CH3), 3.37 (s, 4H, 2NCH2), 7.16 (d, 
4H, J =7.8 Hz), 7.53 (d, 4H, J =7.8 Hz), 8.34 (s, 2H, D2O-exchangeable, 
2NH), 11.66 (s, 2H, D2O-exchangeable, 2NH). [13]C NMR [(CD3)2SO]: δ 
= 20.38, 38.41, 106.74, 111.44, 115.79, 129.49, 133.02, 139.83, 161.29. 
MS m/z (%): 430 (M+, 27.8), 429 (27.8), 368 (33.3), 248 (22.2), 186 
(27.8), 106 (50), 91 (83.3). Anal. Calcd. for C22H22N8O2 (m/z, 430): C, 
61.38; H, 5.15; N, 26.03. Found: C, 61.35; H, 5.12; N, 26.00%. 
N,N'-Ethane-1,2-diylbis[(2-(4-methylbenzoate)hydrazono)-2-
cyanoacetamide] (9b) 
Yield (85%), mp 205 oC (from dioxane). IR (KBr), ν = 3317, 3153 
(2NH), 2211 (C≡N), 1659 (C=O) cm -1; 1H NMR [(CD3)2SO]: δ = 3.30 (s, 
4H, 2NCH2), 3.93 (s, 6H, 2 CH3), 7.20-8.38 (m, 8H, ArH), 8.59 (s, 2H, 
D2O-exchangeable, 2NH), 12.33 (s, 2H, D2O-exchangeable, 2NH). MS 
m/z (%): 486 (M+, 32.0), 356 (13.1), 273 (11.3), 230 (100), 151 (87.4). 
Anal. Calcd for C24H22N8O6 (m/z, 518): C, 55.60; H, 4.28; N, 21.61. 
Found: C, 55.58; H, 4.25; N, 21.60%. 
Synthesis of bis-triazole derivatives 11a,b 
General procedure To a mixture of bis-hydrazone 9a,b (0.01 mol) and 
hydroxylamine hydrochloride (1.40 g, 0.02 mol) in DMF (30 ml), 
anhydrous sodium acetate (0.5 g) was added, and the reaction mixture 
was heated to reflux for 4 h, and then left to cool. The precipitated 
product formed was collected by filtration, dried and then crystallized 
from the appropriate solvent. 
N,N'-ethane-1,2-diylbis[5-amino-2-(4-methylphenyl)-2H-1,2,3-
triazole-4-carboxamide] (11a) 
Yellow crystals, from DMF, m. p.>300 oC, yield 73%. IR (KBr), ν = 3479, 
3333 (NH2, NH), 1649 (C=O) cm-1; 1H NMR [(CD3)2SO]: δ = 2.22 (s, 6H, 
2CH3), 3.31 (s, 4H, 2NCH2), 5.89 (s, 4H, D2O-exchangeable, 2NH2), 7.31-
7.39 (m, 8H, ArH), 7.77 (s, 2H, D2O-exchangeable, 2NH). MS m/z (%): 
460 (M+, 38.5), 210 (46.2), 157 (46.2), 116 (53.8), 105 (15.4), 91(100), 
66 (30.6), 52 (92.3). Anal. Calcd for C22H24N10O2 (m/z, 460): C, 57.38; H, 
5.25; N, 30.42. Found: C, 57.35; H, 5.22; N, 30.40%.  
N,N'-ethane-1,2-diylbis[(methyl 4-(5-amino-2H-1,2,3-triazol-2-
yl)benzoate)-4-carboxamide] (11b) 
Yellow, from DMF, m. p.>300 °C, yield 65%. IR (KBr), ν = 3321, 3220 
(NH, NH2), 1655 (C=O) cm-1. 1H-NMR ([(CD3)2SO]: δ = 2.31 (s, 6H, 
2CH3), 3.32 (s, 4H, 2NCH2), 6.55 (s, 4H, 2NH2), 7.40 (d, 4H, ArH), 7.65 
(d, 4H, ArH), 8.93 (s, 2H, 2NH). MS m/z (%): 550 (M++2, 2.2), 548 (M+, 
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3.4), 533 (2.9), 261 (11.0), 244 (32.7), 216 (3.6), 119 (100), 77 (51.5). 
Anal. Calcd. for C24H24N10O6 (m/z, 548): C, 52.55; H, 4.41; N, 25.54. 
Found: C, 52.51; H, 4.40; N, 25.52%. 
Synthesis of bis-pyrazole derivatives 13a,b 
General procedure To a mixture of bis-hydrazone 9a,b (0.01 mol) and 
chloro- acetonitrile (0.02 mol) in dioxane (40 ml) triethylamine (0.5 
ml) was added, and the reaction mixture was heated under reflux for 6 
h, and then left to cool. The precipitated product was filtered off and 
purified by recrystallization from the suitable solvent to afford the 
corresponding bis-pyrazole derivatives 13a,b. 
N, N'-Ethane-1,2-diylbis[4-amino-5-cyano-1-(4-methylphenyl)-1H-
pyrazole-3-carboxamide] (13a) 
Yellow solid, from dioxane, m. p. 271 oC, yield 84%. IR (KBr), ν = 3347, 
3181 (NH, NH2), 2955 (aliphatic CH), 2211 (C≡N), 1650 (C=O) cm-1. 1H 
NMR [(CD3)2SO]: δ = 2.26 (s, 6H, 2 CH3), 3.37 (s, 4H, 2NCH2), 7.14 (d, 
4H, J = 8.4 Hz), 7.54 (d, 4H, J = 8.4 Hz), 8.37 (s, 4H, D2O-exchangeable, 
2NH2), 11.67 (s, 2H, D2O-exchangeable, 2NH). MS m/z (%): 508 (M+, 
32.4), 452 (22.1), 313 (13.2), 216 (25), 167 (14.7), 157 (20.6), 106 
(58.8), 91 (100), 77 (64.7). Anal. Calcd. for C26H24N10O2 (m/z, 508): C, 
61.41; H, 4.76; N, 27.54. Found: C, 61.40; H, 4.72; N, 27.52%. 
N, N'-Ethane-1,2-diylbis[(methyl 4-(4-amino-5-cyano-1H-pyrazol--
yl)benzoate)-3-carboxamide] (13b)  
Yellow solid, from dioxane, m. p. 221 oC, yield 76%. IR (KBr), ν = 3315, 
3235 (NH, NH2), 2925 (aliphatic CH), 2212 (C≡N), 1645 (C=O) cm-1. 1H 
NMR [(CD3)2SO]: δ = 3.37 (s, 4H, 2NCH2), 3.61 (s, 6H, 2CH3), 7.20 (d, 4H, J 
= 8.4 Hz), 7.52 (d, 4H, J = 8.4 Hz), 8.35 (s, 4H, D2O-exchangeable, 2NH2), 
11.67 (s, 2H, D2O-exchangeable, 2NH). MS m/z (%): 596 (M+, 1.0), 582 
(1.0), 429 (4.1), 311 (42.3), 152 (2.7), 134 (6.3), 116 (1.9), 105 (54.8), 
106 (100), 91 (99.7), 77 (41.6). Anal. Calcd. for C28H24N10O6 (m/z, 596): C, 
56.37; H, 4.06; N, 23.48. Found: C, 56.35; H, 4.05; N, 23.45%. 
Pharmacology 
Diffusion plate well method to determine the antimicrobial 
activity 
The antibacterial and antifungal activity assays were carried out in the 
Medical Mycology Laboratory of the Regional Center for Mycology and 
Biotechnology of Al-Azhar University, Cairo, Egypt using the diffusion 
plate method [32–34] as follows: a bottomless cylinder containing a 
measured quantity (1 ml, 5 mg/ml) of the sample was placed on a plate 
(9 cm diameter) containing a solid bacterial medium (nutrient agar 
broth) or fungal medium, which had been heavily seeded with a spore 
suspension of the test organism. After incubation (24 h for bacteria and 
5 d for fungi), the diameter of the clear zone of inhibition surrounding 
the sample was taken as a measure of the inhibitory power of the sample 
against the particular test organism. The solvent used was DMSO and the 
concentration of the sample used was 100 μg/ml. 
In vitro anticancer activity against human liver cancer cell line 
(HEPG2)  
The method applied is similar to that reported by Vijayan et al. [35] 
using Crystal violet stain (1%). Cells were plated in the 96-multiwell 
plate at a cell concentration (104 cells/well) for 24 h before treatment 
with the tested compound in 100 µl of growth medium. Serial two-fold 
dilutions of the tested chemical compound were added to confluent 
cell monolayers, dispensed into 96-wel, flat-bottomed microtiter plates 
using a multichannel pipette. The microtiter plates were incubated at 
37 °C in a humidified incubator with 5% CO2 for 48 h. Three wells were 
used for each concentration of the test sample. Control cells were 
incubated without test sample with DMSO. After incubation of the cells 
for 24 h at 37 oC, different concentrations of the tested compounds (0, 
1.56, 3.125, 6.25, 12.5, 25, and 50 µg/ml) were added, and the 
incubation was continued for 48 h and the viable cells yield was 
determined by a colorimetric method. After the end of incubation 
period, media were aspirated, and the crystal violet solution was 
added to each well for at least 30 min. The stain was removed, and the 
plates were rinsed using tap water until all excess stain is removed. 
Glacial acetic acid (30%) was then added to all wells and mixed 
thoroughly, and then the absorbance of the plates was measured after 
gently shaken on Microplate reader, using a test wavelength of 490 nm. 
All results were corrected for background absorbance detected in 
wells without added stain. Treated samples were compared with the 
cell control in the absence of the tested compounds. All experiments 
were carried out in triplicate; the results were taken as a mean of three 
determinations. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay and vinblastine were used as a 
reference drug. The relation between surviving fraction and tested 
compound concentration is plotted to get the survival curve of cancer 
cell line and IC50 of each tested compound was calculated. 
RESULTS AND DISCUSSION 
Bis-cyanoacetamide derivatives are active intermediates and excellent 
starting materials for the synthesis of several bis-heterocyclic 
compounds. Thus, the present study began with the Knoevengel 
condensation of bis-cyanoacetamide 1 with the appropriate aromatic 
and heteroaromatic aldehyde 2a-c to give the corresponding bis-
acrylamide derivatives 3a-c in good yield. The structure of the reaction 
products 3a-c were established and confirmed by their elemental 
analysis and spectral data (MS, IR, 1HNMR, [13] CNMR). Thus, the 
structure of 3a is supported by its mass spectrum, which showed a 
molecular ion peak corresponding to the formula C26H28N6O2 (M+, 456). 
Its 1H NMR spectrum showed signals at δ = 3.05 ppm (s, 12H, 4CH3), δ 
= 3.58 ppm (s, 4H, 2NCH2), δ = 6.8 (d, 4H, J = 9.0 Hz, ArH), δ = 7.85 (d, 
4H, J = 9.0 Hz, ArH), δ = 7.96 (s, 2H, 2CH), δ = 8.18 (s, 2H, D2O-
exchangeable, 2NH). Moreover, [13]C NMR spectrum showed the 
presence of peaks at δ = 37.80, 41.70, 75.88, 106.44, 121.11, 127.16, 
142.10, 159.18, 162.32, 171.20 and The IR spectrum revealed 
absorption bands at 1660 (CO), 2197 (CN) and 3348 (NH) (Scheme 1).  
Our study was extended to include the synthesis of new bis-pyrazole 
derivatives. Thus, when the bis-acrylamide derivatives 3a-c was 
reacted under refluxes with hydrazine hydrate in ethanol gave the 
corresponding bis-pyrazole 4a-c in good yields. The structure of the 
reaction products 4a-c were established and confirmed by their 
elemental analysis and spectral data (MS, IR, 1H NMR). Thus, the 
structure of 4a is supported by its mass spectrum, which showed a 
molecular ion peak corresponding to the formula C26H32N10O2 (M+, 
516). 1H NMR spectrum showed signals at δ = 3.08 ppm (s, 12H, 4CH3), 
δ = 3.31 ppm (s, 4H, 2CH2), δ = 6.87 ppm (s, 4H, 2NH2), δ = 7.35 ppm (d, 
4H, ArH), δ = 7.94 ppm (d, 4H, ArH), δ = 9.47 ppm (s, 2H, 2NH), δ = 
10.39 ppm (s, 2H, 2NH) and The IR spectrum revealed absorption 




































   a: 4-NMe2C6H4
   b: 4-NO2C6H4
   c: 4-1,3-diphenyl-1H-pyrazole
 
Scheme 1: Synthesis of N, N'-Ethane-1,2-diylbis[3-aryl-2-
cyanoacrylamide] (3a-c) and bis-pyrazole derivatives 4a-c 
 
In view of the growing biological importance of thiazole derivatives, it 
was considered of interest to synthesizing some new bis-thiazoles. 
Thus, cyclocondensation of bis-cyanoacetamide 1 with thioglycolic acid 
in refluxing acetic acid afforded bis-thiazole derivative 6 was 
confirmed on the basis of elemental analysis, spectral data 1H NMR 
spectrum showed signals at δ = 3.12 ppm (s, 4H, 2CH2); δ = 3.59 (s, 4H, 
2NCH2); 5.56 (s, 2H, 2CH), 7.72 (s, 2H, 2NH), 11.23 (s, 2H, 2OH). The IR 
spectrum revealed absorption bands at 3397 (NH), 1716 (C=O), 1635 
(C=O). A formation of 6 is assumed to proceed via the initial 
nucleophilic addition of the mercapto function to the Nitrile group, 
followed by intramolecular cyclization and elimination of the two 
water molecules to afford thiazole derivative 6 (scheme 2).  
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Also, the bis-cyanoacetamide 1 were reacted with sulfur and phenyl 
isothiocyanate in refluxing ethanol containing a catalytic amount of 
triethylamine, afforded N, N'-Ethane-1,2-diylbis(4-amino-3-phenyl-2-
thioxo-2,3-dihydrothiazole-5-carboxamide) (7) The structure of the 
reaction product 7 was confirmed by their elemental analysis and 
spectral data (MS, IR, 1H NMR). Thus, a structure of 7 is supported by 
its mass spectrum, which showed a molecular ion peak corresponding 
to the formula C22H20N6O2S4 (M+, 528). The 1H NMR spectrum showed 
signals at δ = 3.28 ppm (s, 4H, 2CH2), δ = 6.70 ppm (s, 4H, 2NH2), δ = 
7.33-7.36 ppm (m, 4H, ArH), δ = 7.57-7.65 ppm (m, 8H, ArH+2NH) and 
The IR spectrum revealed bands at 3437, 3367, 3250 (NH, NH2), 1618 




























































Scheme 2: Synthesis of bis-thiazol derivatives 6 and 7 
 
Next, coupling products derived from reactions of diazonium salts with 
active methylene compounds are widely used as intermediates for the 
synthesis of a large number of heterocyclic compounds [36-38]. Also, 
heterocyclic azo compounds are well known for their use as 
antineoplastics, [39] antidiabetics, [40] antiseptics, [41] antibacterial, 
[42] and are known to be involved in a number of biological reactions 
such as inhibition of DNA, RNA and protein synthesis, carcinogenesis 
and nitrogen fixation [41,43]. Thus, bis-cyanoacetamide 1 coupled with 
diazonium salts 8a,b derived from the appropriate aromatic amines (4-
methylaniline and 4-methoxycarbonylaniline) in EtOH buffered with 
sodium acetate, to afford the respective hydrazones 9a,b (scheme 3). 
The structure of the reaction products 9a, b was confirmed by their 
elemental analysis and spectral data (MS, IR, 1H NMR, [13]C NMR). 
Thus, the structure of 9a is supported by its mass spectrum, which 
showed a molecular ion peak corresponding to the formula C22H22N8O2 
(M+, 430). The 1H NMR spectrum showed signals at δ = 2.26 ppm (s, 6H, 
2 CH3), δ = 3.37 ppm (s, 4H, 2NCH2), δ = 7.16 ppm (d, 4H, J = 7.8 Hz), δ 
= 7.53 ppm (d, 4H, J = 7.8 Hz), δ = 8.34 ppm (s, 2H, D2O-exchangeable, 
2NH), δ = 11.66 ppm (s, 2H, D2O-exchangeable, 2NH). Moreover, [13]C 
NMR spectrum showed the presence of peaks at δ = 20.38, 38.41, 
106.74, 111.44, 115.79, 129.49, 133.02, 139.83, 161.29 and The IR 
spectrum revealed absorption bands at 3315, 3235 (2NH), 2925 
(aliphatic CH), 2212 (C≡N), 1645 (C=O) . In the 1H NMR spectra of 
compounds 9a, b indicated that the absence of signal assignable to 
azomethine group (CH-N=N-) [44] at δ = 3.00-4.00 ppm ruled out azo 
form and support the hydrazone structure of the reaction products. 
Also compounds 9a,b reacted with hydroxylamine hydrochloride in 
refluxing DMF containing a catalytic amount of anhydrous sodium 
acetate give bis-triazole-4-carboxamide derivatives 11a,b The 
structure of the reaction products 11a,b were determined and 
confirmed by their elemental analysis and spectral data (MS, IR, 1H 
NMR). Thus, the structure of 11a is supported by its mass spectrum, 
which showed a molecular ion peak corresponding to the formula 
C22H24N10O2 (M+, 460). The 1H NMR spectrum showed signals at δ = 
2.22 (s, 6H, 2CH3), δ = 3.31 ppm (s, 4H, 2NCH2), δ = 5.89 ppm (s, 4H, 
D2O-exchangeable, 2NH2), δ = 7.31-7.39 ppm (m, 8H, ArH), δ = 7.77 
ppm (s, 2H, D2O-exchangeable, 2NH) and The IR spectrum revealed 
absorption bands at 3479, 3333 (NH2, NH), 1649 (C=O). The formation 
of 11 from 9 and hydroxylamine hydrochloride is assumed to proceed 
via an initial addition of the amino group of hydroxylamine to the 
cyano moiety in the hydration 9a, b to form intermediates 10, followed 
by intramolecular cyclization via elimination of two water molecules to 





















































































     a: 4-CH3C6H4
     b: 4-CO2CH3C6H4  
Scheme 3: Synthesis of bis-triazol and bis-pyrazol derivatives 11a,b and 13a,b 
 
Furthermore, treatment of hydrazone 9a,b with chloro- acetonitrile in 
refluxing dioxane containing a catalytic amount of triethylamine 
afforded the bis-pyrazole derivatives 13a,b in good yields. The 
structure of the reaction products 13a,b were confirmed from their 
elemental analysis and spectral data (MS, IR, 1H NMR). Thus, the 
structure of 13a is supported by its mass spectrum, which showed a 
molecular ion peak corresponding to the formula C26H24N10O2 (M+, 
508). The 1H NMR spectrum showed signals at δ = 2.26 ppm (s, 6H, 2 
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CH3), δ = 3.37 ppm (s, 4H, 2NCH2), δ = 7.14 ppm (d, 4H, J = 8.4 Hz), δ = 
7.54 ppm (d, 4H, J = 8.4 Hz), δ = 8.37 ppm (s, 4H, D2O-exchangeable, 
2NH2), δ = 11.67 ppm (s, 2H, D2O-exchangeable, 2NH) and The IR 
spectrum revealed absorption bands at 3347, 3181 (NH, NH2), 2955 
(aliphatic CH), 2211 (C≡N), 1650 (C=O ). The formation of 13 from 9 
and chloro- acetonitrile is assumed to proceed via intermediary 12 
(Scheme 3).  
Antimicrobial screening 
The in vitro antimicrobial activity of newly synthesized compounds 3a-
c, 4a-c, 6, 7, 9a,b, 11a,b and 13a,b were determined against Gram-
positive bacteria as Staphylococcus aureus (RCMB-010010) (SA) and 
Bacillis subtilis (RCMB-010067) (BS) and Gram-negative bacteria as 
Pseudomonas aeruginosa (RCMB-010043) (PA) and Escherichia coli 
(RCMB-010052) (EC). They were also determined against antifungal 
activity as Aspergillus fumigatus (RCMB-02568) (AF), Syncephalastrum 
racemosum (RCMB-05922) (SR), Geotricum candidum (RCMB-05097) 
(GC) and Candida albicans (RCMB-05036) (CA) fungal strains. 
Inhibition zone diameter (IZD) in mm was used as the criterion for the 
antimicrobial activity using the diffusion technique [40-42]. The 
fungicide Amphotericin B and the bactericides Ampicillin and 
Gentamicin were used as references to determine the potency of the 
new tested compounds [45]. The results are given in (table 1) and 
(table 2). 
  
Table 1: Antimicrobial activities of the new compounds 
Compd no. Diameter of inhibition zone in (mm) 
Gram (+) Gram (-) 
(SA) (BS) (PA) (EC) 
3a 15.2±0.21 16.9±0.08 NA 11.8±0.5 
3b 14.1±0.5 14.8±0.10 NA 9.3±0.5 
3c NA NA NA NA 
4a 17.4±0.04 19.2±0.03 NA 13.7±0.04 
4b 14.9±0.01 15.9±0.03 NA 11.2±0.5 
4c 18.9±0.01 19.9±0.03 NA 15.8±0.5 
6 9.8±0.2 10.4±0.30 8.3±0.1 10.9±0.3 
7 10.3±0.55 11.3±0.25 10.3±0.55 11.3±0.25 
9a 17.3±0.09 20.3±0.08 11.9±0.05 17.9±0.02 
9b 20.1±0.04 22.4±0.07 15.8±0.09 22.4±0.08 
11a 13.2±0.01 14.3±0.07 NA 8.3±0.2 
11b 23.7±0.03 25.2±0.04 20.4±0.06 24.4±0.04 
13a 14.4±0.01 15.2±0.03 NA 10.4±0.2 
13b 17.4±0.04 19.2±0.03 NA 13.7±0.04 
Ampicillin 23.8±0.2 32.4±0.3 - - 
Gentamicin - - 17.3±0.1 19.9±0.3 
*NA: No activity, data is expressed in the form of mean±SD 
*Data are expressed in the form of mean±SD. Mean zone of inhibition in mm±standard deviation beyond the well diameter; (6 mm) produced on a 
range of environmental and clinically pathogenic microorganism using (5 mg/ml) concentration of testing sample (100 µl was tested). 
 
Table 2: Antifungal activities of the new compounds 
Compd no. Diameter of inhibition zone in (mm) 
(AF) (SR) (GC) (CA) 
3a 15.9±0.08 NA 18.7±0.5 15.6±0.1 
3b 10.2±0.03 NA 13.1±0.04 13.8±0.03 
3c 12.6±0.25 NA NA 11.2±0.33 
4a 12.4±0.07 NA 11.5±0.05 NA 
4b 13.4±0.08 NA 15.3±0.3 16.2±0.08 
4c 15.5±0.08 NA 12.9±0.2 13.9±0.1 
6 10.2±0.55 NA 10.5±0.1 12.6±0.33 
7 11.3±0.44 NA 14.3±0.4 12.9±0.25 
9a 19.3±0.3 9.3±0.08 17.4±0.09 18.1±0.1 
9b 21.3±0.2 19.5±0.05 19.9±0.08 10.2±0.03 
11a 12.3±0.07 NA 14.9±0.2 12.4±0.3 
11b 23.3±0.08 16.9±0.07 21.4±0.1 20.1±0.05 
13a 11.6±0.1 NA 14.2±0.08 14.9±0.2 
13b 12.4±0.07 NA 10.5±0.04 11.5±0.05 
Amphotericin B 23.7±0.2 19.7±0.2 28.7±0.2 25.4±0.1 
*NA: No activity, data is expressed in the form of mean±SD 
*Data are expressed in the form of mean±SD. Mean zone of inhibition in mm±standard deviation beyond the well diameter; (6 mm) produced on a 
range of environmental and clinical pathogenic microorganism using (5 mg/ml) concentration of testing sample (100 µl was tested). 
 
As shown in this tables, Staphylococcus aureus, and Bacillis subtilis 
are sensitive to all tested compounds except compounds 3c; 
furthermore, Pseudomonas aeruginosa is sensitive to compounds 6, 
7, 9a,b and 11a, while Escherichia coli is sensitive to all tested 
compounds except compound 3c. All tested compounds exhibit 
antifungal activity against the Aspergillus fumigatus. Also 
Syncephalastrum racemosum is sensitive to three compounds 9a, b, 
and 11b. All tested compounds except compound 3c and 4a exhibit 
antifungal activity against the two tested fungi species Geotricum 
candidum and Candida albicans, respectively. Compounds 4a-c, 9a,b, 
11b and 13b have highest antimicrobial activity values is attributed 
to the presence of pharmacological active pyrazole moiety in 
compounds 4a-c and 13b, a cyanoazo moiety in compounds 9a,b, 
triazole ring in compound 11b. 
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Anticancer screening 
The anticancer effects of newly synthesized compounds against a 
human liver cell line (HEPG-2) were evaluated. The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 
and vinblastine were used as a reference to evaluate the drug potential 
of testing compounds. Five various concentrations of each compound 
and the references were used in such screening tests [46]. Anticancer 
activity was expressed as the mean IC50 of three independent 
experiments (table 3), (fig. 1) and (fig. 2). 
  
Table 3: In vitro anticancer activity of the new compounds against HEPG-2 Cell Line 









3.125 µg/ml 1.56 µg/ml 0 µg/ml 
 Surviving fraction 
Vinblastine 14.38 16.13 24.25 45.13 55.00 72.13 100 4.6 
3a 8.58 19.32 23.08 56.84 69.75 84.58 100 7.5 
3b 6.80 18.42 61.43 79.96 88.04 96.02 100 15.8 
3c 11.56 26.34 39.18 68.47 89.05 93.78 100 10.2 
4a 6.08 11.23 16.79 31.17 69.38 86.94 100 4.2 
4b 9.03 21.84 64.21 82.19 89.72 94.38 100 16.7 
4c 9.12 16.31 55.87 64.10 79.39 86.36 100 14.3 
6 18.94 32.46 57.61 81.42 92.08 98.93 100 16.3 
7 10.28 21.31 32.72 49.58 57.23 70.97 100 6.1 
9a 10.92 21.78 34.53 53.49 64.72 81.86 100 7.4 
9b 6.67 16.43 27.28 43.87 65.69 89.14 100 5.6 
11a 13.92 25.06 60.38 72.63 87.84 95.76 100 16.1 
11b 31.74 43.38 48.59 59.76 71.24 89.47 100 11.6 
13a 38.8 60.32 78.18 93.25 98.91 100 100 36.8 

























Fig. 1: Effect of the compounds 3a-c, 4a-c and 6 on cellular viability (HEPG-2 cells); Values are the mean of three independent 
























Fig. 2: Effect of the compounds 7, 9a,b, 11a,b and 13a on cellular viability (HEPG-2 cells), Values are the mean of three independent 
experiments; a standard deviation of twofold was judged acceptable 
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Data generated were used to plot a dose-response curve of which the 
response parameter IC50 value, which corresponds to the 
concentration of test compounds required to kill 50 % of cell 
population was calculated. According to Shier [47] the compounds 
exhibiting IC50 activity within the range of 10–25 μg/ml is considered 
weak anticancer agents while those of IC50 activity between 5 and 10 
μg/ml are moderate and compounds of activity below 5.00 μg/ml are 
considered strong agents. The results are given in table 3. As shown in 
this table, and according to Shier [43]. Compound 4a have highest 
anticancer values, compounds 3a, 7 and 9a,b are moderate while the 
ether tested compounds are weak against a human liver cell line 
(HEPG-2). 
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